Annaly Capital Management Inc. recently revealed that the board has elected Thomas Hamilton, former Global Head of Securitized Product Trading and Banking and Head of Municipal Trading and Banking at Barclays Capital, as an independent member of the Board. Annaly takes a strategic approach to board composition with the addition of Hamilton, which brings the Board to 13 members, 11 of whom are independent, according to a prepared statement.
“Tom adds deep financial services acumen to our Board across a number of investment strategies fundamental to Annaly’s business,” said Kevin Keyes, Chairman, Chief Executive Officer and President. “Tom has a phenomenal reputation and is a proven expert and leader in our industry with decades of experience across the fixed income arena – with particular proficiency in mortgage markets and securitized products, risk management and business strategy.” Keyes continued, “The Directors we have named over the past two years align with Annaly’s continued strategic evolution and enhance the Board’s expertise across a number of dimensions, including corporate governance, accounting, public policy, human resources and global financial services. We welcome Tom to our Board and look forward to the value his business insight and leadership will contribute to the future of our Company.”
Hamilton has served as the President, Chief Executive Officer and Owner of Construction Forms, Inc., an industrial manufacturing company, since 2013. Prior to his current position, Hamilton spent 24 years in a number of leadership positions in the financial industry.
Most recently, Hamilton served as Strategic Advisor to the Global Head of Fixed Income, Currencies and Commodities at Barclays Capital in New York. Hamilton’s prior roles at Barclays include serving as the Global Head of Securitized Product Trading and Banking, in which capacity he was responsible for the build out of Barclay’s Global Securitized Product businesses, and as the Head of Municipal Trading and Banking. Prior to Barclays, Hamilton held various Managing Director roles at Citigroup, Inc. and Salomon Brothers, Inc., where he began his career.
Hamilton also serves as Chairman of the Board of Chondrial Therapeutics Inc., a biotech company he started to cure a rare neurodegenerative disease called Friedreich’s Ataxia. He is also a Director of the Friedreich’s Ataxia Research Alliance, along with Co-Founder of his own charitable scientific effort, the CureFA Foundation.
Given the Company’s declassification of the Board in December of 2018, Hamilton will stand for re-election to the Board at the Company’s 2019 Annual Meeting of Stockholders for a term of one year. Hamilton has been appointed to the Board’s Audit Committee and Risk Committee.